Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

  • Filters activated: Toxicology. Clear all to show 101 items.
1.

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y.

Cancer Chemother Pharmacol. 2019 Oct;84(4):891-898. doi: 10.1007/s00280-019-03929-9. Epub 2019 Aug 23.

2.

TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo.

Akcora BÖ, Dathathri E, Ortiz-Perez A, Gabriël AV, Storm G, Prakash J, Bansal R.

FASEB J. 2019 Aug;33(8):9466-9475. doi: 10.1096/fj.201900215RR. Epub 2019 May 17.

PMID:
31100032
3.

RANKL-mediated osteoclastogenic differentiation of macrophages in the abdominal aorta of angiotensin II-infused apolipoprotein E knockout mice.

Tanaka T, Kelly M, Takei Y, Yamanouchi D.

J Vasc Surg. 2018 Dec;68(6S):48S-59S.e1. doi: 10.1016/j.jvs.2017.11.091. Epub 2018 Apr 21.

4.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12.

PMID:
29650801
5.

ETS transcription factor ELF5 induces lumen formation in a 3D model of mammary morphogenesis and its expression is inhibited by Jak2 inhibitor TG101348.

Chean J, Chen CJ, Shively JE.

Exp Cell Res. 2017 Oct 1;359(1):62-75. doi: 10.1016/j.yexcr.2017.08.008. Epub 2017 Aug 8.

PMID:
28800960
6.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
7.

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E.

Mol Cancer Ther. 2017 Jun;16(6):1054-1067. doi: 10.1158/1535-7163.MCT-16-0568-T. Epub 2017 Mar 23.

8.

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.

Quan Y, Xu H, Han Y, Mesplède T, Wainberg MA.

J Virol. 2017 Apr 13;91(9). pii: e00075-17. doi: 10.1128/JVI.00075-17. Print 2017 May 1.

9.

IL-5 blocks apoptosis and tau hyperphosphorylation induced by Aβ25-35 peptide in PC12 cells.

Zhou Y, Li C, Li D, Zheng Y, Wang J.

J Physiol Biochem. 2017 May;73(2):259-266. doi: 10.1007/s13105-017-0550-8. Epub 2017 Jan 28.

PMID:
28132394
10.

Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy.

Hazell AS, Afadlal S, Cheresh DA, Azar A.

Neurosci Lett. 2017 Mar 6;642:163-167. doi: 10.1016/j.neulet.2017.01.041. Epub 2017 Jan 18.

PMID:
28109775
11.

Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.

Swerev TM, Wirth T, Ushmorov A.

Int J Oncol. 2017 Feb;50(2):555-566. doi: 10.3892/ijo.2016.3827. Epub 2016 Dec 30.

PMID:
28035374
12.

Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.

Giacomini MM, Hao J, Liang X, Chandrasekhar J, Twelves J, Whitney JA, Lepist EI, Ray AS.

Drug Metab Dispos. 2017 Jan;45(1):76-85. Epub 2016 Nov 1. Erratum in: Drug Metab Dispos. 2017 Nov;45(11):1146-1147.

PMID:
27803021
13.

Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.

Lim KH, Chang YC, Chiang YH, Lin HC, Chang CY, Lin CS, Huang L, Wang WT, Gon-Shen Chen C, Chou WC, Kuo YY.

Blood Cancer J. 2016 Oct 7;6(10):e481. doi: 10.1038/bcj.2016.83.

14.

Safety considerations when treating myelofibrosis.

O'Sullivan JM, McLornan DP, Harrison CN.

Expert Opin Drug Saf. 2016 Sep;15(9):1185-92. doi: 10.1080/14740338.2016.1185414. Epub 2016 Jun 1. Review.

PMID:
27187785
15.

Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.

Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):315-21. doi: 10.1002/cpdd.161. Epub 2014 Oct 27.

PMID:
27136912
16.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.

Curto-García N, Harrison CN, McLornan DP, Radia DH.

Br J Haematol. 2017 Jul;178(2):338-340. doi: 10.1111/bjh.14128. Epub 2016 May 2. No abstract available.

PMID:
27135305
17.

Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.

Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M.

Sci Rep. 2015 Sep 30;5:14538. doi: 10.1038/srep14538.

18.

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.

Gunerka P, Dymek B, Stanczak A, Bujak A, Grygielewicz P, Turowski P, Dzwonek K, Lamparska-Przybysz M, Pietrucha T, Wieczorek M.

Eur J Pharmacol. 2015 Oct 15;765:188-97. doi: 10.1016/j.ejphar.2015.08.037. Epub 2015 Aug 20.

PMID:
26300391
19.

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M.

Blood Cancer J. 2015 Aug 7;5:e335. doi: 10.1038/bcj.2015.63.

20.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A.

JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.

PMID:
26181658

Supplemental Content

Loading ...
Support Center